Related references
Note: Only part of the references are listed.Cerebrospinal Fluid Concentrations of Gefitinib in Patients With Lung Adenocarcinoma
Jing Zhao et al.
CLINICAL LUNG CANCER (2013)
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
Takashi Kobayashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Yosuke Togashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
N. R. Budha et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
Francois Guilhot et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient
Yukari Tsubata et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2012)
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature
R. ter Heine et al.
LUNG CANCER (2012)
Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
Pascaline Boudou-Rouquette et al.
PLOS ONE (2012)
Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer
Akinobu Hamada et al.
PHARMACOGENOMICS (2012)
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
Pei-pei Dong et al.
ACTA PHARMACOLOGICA SINICA (2011)
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
A. C. Mita et al.
BRITISH JOURNAL OF CANCER (2011)
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
Eric H. Kraut et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation
Mohamed A. Elmeliegy et al.
CLINICAL CANCER RESEARCH (2011)
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Astrid A. M. van der Veldt et al.
CLINICAL CANCER RESEARCH (2011)
Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children
Melanie White-Koning et al.
CLINICAL CANCER RESEARCH (2011)
An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs
Viet Hong Phan et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2011)
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer
Yosuke Togashi et al.
LUNG CANCER (2011)
Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
Yun-Ju Chen et al.
PLOS ONE (2011)
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
T. Mizuno et al.
ANNALS OF ONCOLOGY (2010)
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
Joline S. W. Lind et al.
CLINICAL CANCER RESEARCH (2010)
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Luis Paz-Ares et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
Jennifer L. Clarke et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
Wee-Lee Yeo et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer The Okayama Lung Cancer Study Group Experience
Katsuyuki Hotta et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations Okayama Lung Cancer Study Group Trial 0705
Hiroshige Yoshioka et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Erlotinib and Gastrointestinal Ulcer
Young Hak Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
Yoichi Nakamura et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
A Case of Radiation Recall Pneumonitis Induced by Erlotinib, Which Can be Related to High Plasma Concentration
Yosuke Togashi et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations
Satoshi Morita et al.
CLINICAL CANCER RESEARCH (2009)
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
Fabienne Thomas et al.
EUROPEAN JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
Nielka P. van Erp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
Vincent A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice
Serena Marchetti et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
Jing Li et al.
CANCER BIOLOGY & THERAPY (2007)
ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy
Alberto Lazarowski et al.
EPILEPSIA (2007)
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
George Cusatis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
Jing Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Clinical pharmacokinetics of erlotinib in patients with solid tumors and. exposure-safety relationship in patients with non-small cell lung cancer
Jian-Feng Lu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton et al.
CLINICAL CANCER RESEARCH (2006)
Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient
C Moreau et al.
TRANSPLANTATION (2006)
Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients
Miwa Uesugi et al.
PHARMACOGENETICS AND GENOMICS (2006)
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
Y Nagai et al.
CANCER RESEARCH (2005)
FDA drug approval summary:: Erlotinib (Tarceva®) tablets
MH Cohen et al.
ONCOLOGIST (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients
P Breedveld et al.
CANCER RESEARCH (2005)
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection
WJ Zhang et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition
FA de Jong et al.
CLINICAL CANCER RESEARCH (2004)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
I Cascorbi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
